explore -WSS

explore

author：explore 2025-09-30 00:36:17 - browse：62894

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Congress likely to miss an opportunity to fix drug shortages issue

hotspot

Wikipedia

WSS

Will generative AI in health care meet the fate of IBM's Dr. Watson?

The new HIV moral panic

FDA's naming rule on biosimilars has undermined competition

Blood tests recalled over risk of missed heart attack diagnosis

States should stop sabotaging methadone treatment reform

Washington mulls new rules to avert another Change Healthcare

knowledge

explore

hotspot

In Memoriam: Notable people who died in 2023

Celiac disease study examines precisely how gluten triggers injury

Apple is now the first public company to be valued at $3 trillion

Abortion pill Supreme Court ruling could impact entire drug industry

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Cancer drug shortages should be causing more outrage

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Washington mulls new rules to avert another Change Healthcare

leisure time

Care demand spikes challenge UnitedHealth’s provider arm

Merck drug for rare lung condition set for approval in U.S.

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Oprah kicked off a national conversation on obesity. Let's have it

There's no autism epidemic. It's an autism diagnosis epidemic

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

hotspot

Wikipedia

hotspot

leisure time